Overall, to our knowledge, we demonstrated that TET2-related epitranscriptomic modification and Bobcat339-targeting treatment constitute a pioneering epigenetics-based approach and protein-binding structure simulation-based strategy for discovering novel lead compounds and effective therapeutics for treating COVID-19 and new emergent life-threatening infections. Here, TET2 is linked to infection.